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a  b  s  t  r  a  c  t
Copy  number  variations  (CNVs)  contribute  to  neuropsychiatric  diseases,  which  may  be partly  medi-
ated  by their  effects  on  gene  expression.  However,  few studies  have  assessed  the  inﬂuence of CNVs
on  gene  expression  in  the  brain.  The  objective  was  to  perform  an unbiased  comprehensive  survey
of  inﬂuence  of  CNVs  on  gene  expression  in  human  brain  tissues.  CNV  regions  (CNVRs)  were  identi-
ﬁed  in  72 individuals  (23 schizophrenia,  23 bipolar  disorder  and 26  controls).  Signiﬁcant  associations
between  the  CNVRs  and  gene  expression  levels  were  observed  for 583  CNVR-expression  probe  pairs
(293  unique  eCNVRs  and  429  unique  transcripts),  after  corrections  for  multiple  testing  and  controlling
the  effect  of the  number  of  subjects  with  CNVRs  by  label  swapping  permutations.  These  CNVRs  affect-
ing  gene  expression  (eCNVRs)  were  signiﬁcantly  enriched  for  rare/low  frequency  (p = 1.087  × 10−10)  andipolar disorder
ranscriptome
enomics
gene-harboring  CNVRs  (p  = 1.4 × 10−6). Transcripts  overlapping  CNVRs  were  signiﬁcantly  enriched  for
glutathione  metabolism  and  oxidative  stress  only  for cases  but  not  for controls.  Moreover,  72 (24.6%)  of
eCNVRs  were located  within  the  chromosomal  aberration  regions  implicated  in psychiatric-disorders:
16p11.2,  1q21.1,  22q11.2,  3q29,  15q11.2,  17q12  and 16p13.1.  These  results  shed  light  on  the  mechanism
of  how  CNVs  confer  a risk  for  psychiatric  disorders.
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. IntroductionA key objective in genetic research is to link genomic variation
o phenotype differences to uncover normal as well as patholog-
cal variation. The inﬂuence of single nucleotide polymorphisms
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on phenotypic variation has been extensively studied; however, it
is only recently that other DNA alterations such as copy number
variations are being investigated. Copy number variations (CNVs)
are DNA segments present at variable copy numbers and owing
to their large size, contribute to a substantial proportion of the
variation in the human genome (Ionita-Laza et al., 2009; Redon
et al., 2006). Among the CNVs, rare CNVs are of more interest
because they are presumably enriched in de novo events. Under
the rare-variant common disease hypothesis, multiple rare vari-
ants with high effect sizes in aggregation, contribute substantially
to the illness, hence these rare variants are of great interest since
they have not been subject to selection as yet (Zhang et al., 2009).
Rare copy number variations have been reported in individuals
with neurological and psychiatric disorders such as schizophre-
nia (International Schizophrenia Consortium, 2008; Levinson et al.,
2011; McCarthy et al., 2009), autism (Hedges et al., 2012), bipo-
lar disorder (Zhang et al., 2009) and mental retardation (Guilmatre
et al., 2009).
Open access under CC BY-NC-ND license.Although a large number of CNVs have been identiﬁed in a vari-
ety of different species and range of diseases, the functional impact
of CNVs at the molecular level remains largely unexplored. One way
to assess the functional impact of copy number variations is via its
ence Society. Open access under CC BY-NC-ND license.
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ffect on different cellular processes such as gene expression levels.
he initial study exploring the transcriptome-wide impact of CNVs
n gene expression proﬁles in lymphoblastoid cell lines (LCLs) iden-
iﬁed that approximately 20% of variation in gene expression could
e attributed to copy number variations in the genome (Stranger
t al., 2007). While there is a plethora of studies assessing the
nﬂuence of single nucleotide polymorphisms on gene expression
roﬁles, to the best of our knowledge, there are only four studies
nterrogating the inﬂuence of CNVs on gene expression in humans.
oreover, due to the limited availability of human tissues such as
rain samples, three of the four studies assessing the inﬂuence of
NVs on gene expression in normal tissues till date have been per-
ormed on LCLs (Luo et al., 2012; Schlattl et al., 2011; Stranger et al.,
007) while only one recent study (Ye et al., 2012) has assessed gene
xpression in the human brain.
Integration of gene expression and CNV data will allow the pri-
ritization of CNV-harboring candidate regions where the CNVs
igniﬁcantly alter gene expression levels of transcripts thereby
roviding evidence of a downstream functional consequence. The
im of this study was to perform a comprehensive and unbiased
enome-wide search for functional CNVs in the human brain and
o interrogate the nature of these CNVs.
. Materials and methods
.1. Samples
Gene expression and copy number variations (CNVs) were
btained from prefrontal cortices of postmortem brains of 105 indi-
iduals (35 controls, 35 bipolar disorder [one of which was later
xcluded due to the alteration of diagnosis] and 35 schizophrenia
atients) from the Stanley Medical Research Institute. As described
n our previous report (Iwamoto et al., 2011), to reduce confound-
ng factors due to previously identiﬁed effects of sample pH, we
nterrogated 72 individuals (26 controls, 23 bipolar disorder and 23
chizophrenia patients) which were preselected for high pH levels
pH ≥ 6.4).
.2. Gene expression
Gene expression levels were assessed using the Affymetrix
U133A microarray which comprised of 22,283 expression probes,
etails of which are described elsewhere (Iwamoto et al., 2011).
rieﬂy, the raw gene expression data was preprocessed using
AS5 (Affymetrix) and ﬁltered for probes which were called
resent in more than 50% of the samples, allowing a total of
1,920 probes for subsequent analysis. Microarray data had been
eposited to the GEO database and is available on the GEO server
GES12649) and on the Stanley Medical Research Institute database
https://www.stanleygenomics.org/).
.3. Copy number variation
Copy number variation was measured on the Agilent 450k early
ccess CGH array (Agilent Technologies, Inc., Santa Clara, CA, USA),
hich is designed based on the database of known CNVs. Sample
nd reference DNA (3.0 g each) was labeled with Cy5 or Cy3 using
he DNA labeling kit from Agilent. Hybridization and washes were
erformed following the manufacturer’s recommendation. The
rrays were scanned with a MicroArray Scanner G2505A (Agilent).
he obtained TIFF image data were processed with Agilent Feature
xtraction software (version 9.5.3.1) using the CGH-v4 95 Feb07
rotocol (Agilent).
DNA from one female (NA15510, Coriell Cell Repository, Cam-
en, NJ, USA) was used as a reference to allow detection of copy
umber changes. This was in accordance with previous reportsesearch 79 (2014) 22–33 23
which have shown that usage of a single reference increases the
sensitivity to detect more CNVs and produces more consistent
and reproducible data as compared to using a pooled reference
(Haraksingh et al., 2011). The raw data were imported into Agi-
lent DNA Analytics 70 software and analyzed using the Aberration
Detection Method 2 (ADM-2) algorithm (Lipson et al., 2006) which
uses log2 ratios weighted by log2 ratios error as calculated by Fea-
ture Extraction software to identify genomic intervals with copy
number differences between the samples and the reference. The
Agilent Feature Extraction software was used to compute Qual-
ity Control metrics. The Agilent protocol recommended thresholds
including average signal intensity at each probe, background signal
(noise) (<5) using non-hybridizing control probes and signal-to-
noise ratios (>30) were used to assess the quality of DNA and the
experimental workﬂow. The derivative log ratio spread (dLRsd) was
used to calculate the robust standard deviation (spread) of the log
ratio differences between consecutive probes across all chromo-
somes. Three samples that did not satisfy the QC metrics thresholds
and had dLRsd of >0.30 were excluded from further analysis.
The following parameters were used in this analysis: threshold
of ADM-2: 6.0 with a bin size of 10; fuzzy zero: on; GC cor-
rection: on, aberration ﬁlters: on (maxAberrations = 100,000 AND
percentPenetrance = 0); feature level ﬁlters: on (gIsSaturated = true
OR rIsSaturated = true OR gIsFeatNonUnifOL = true OR rIsFeatNon-
UnifOL = true). A minimum three contiguous suprathreshold probes
were mandatory to deﬁne a copy number change. Data were cen-
tralized and calls with average log2 ratios of ≤0.25 were excluded
from the analysis. Data were normalized using the GC  correction
algorithm that corrects for wavy artifacts associated with the GC
content of genomic regions and fuzzy zero correction that allows
correction of extended aberrant segments with low absolute mean
ratios that might represent noise. In the current study we assessed
only autosomal CNVs since analysis of X and Y chromosomal CNVs
are difﬁcult to interpret. After ﬁltering, a total of 34,453 CNV probes
corresponding to 6836 copy number variable regions (CNVRs) were
used for the analysis.
2.4. Statistical analysis
Physical positions and annotations of the gene expres-
sion and CNV array probes were updated to the Genome
build GRCh37 (hg19) using the UCSC genome browser Liftover
tool (http://genome.ucsc.edu/cgi-bin/hgLiftOver). Separate analy-
sis was performed for the continuous log2 CNV ratio and the
simpliﬁed CNV state (1 = loss, 2 = normal state and 3 = gain) for each
CNVR. A log2 ratio of 0 was considered the normal state, a log2 ratio
of <−0.25 was considered a loss and log2 ratio of >0.25 was  consid-
ered a gain. To identify the inﬂuence of CNVRs on gene expression,
for each CNVR we  probed a cis-window of ±1 Mb  from the CNVR
coordinates. For all gene expression probes located fully or par-
tially (at least 1 bp overlap) within this window, we  calculated the
association between the CNVR state/CNVR log-ratio and the gene
expression levels using general linear models (glm) in R, whilst co-
varying for age, gender, ethnicity and post-mortem interval (PMI)
hours and the results were corrected for multiple testing using 5%
false discovery rate (fdr). Results of the association between the
CNVR state/CNVR log-ratio and the gene expression levels were
very similar, therefore only the results for the CNVR state are pre-
sented.
To correct for the different numbers of gene expression probes
tested for each CNVR and to account for possible inﬂation in asso-
ciation p-values which might result due to outliers especially for
the singletons, we  repeated the association analysis using label-
swapping adaptive permutations with a maximum of 100,000
permutations in PLINK (Purcell et al., 2007). This method is widely
accepted as the most appropriate method for multiple testing
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orrection and allows for outlier detection (Gibbs et al., 2010; Luo
t al., 2012) since it does not assume the normal distribution of the
rait and calculates the empirical p-value by label-swapping of the
uantitative trait by randomly assigning each individuals quantita-
ive trait (gene expression level) to another individuals CNVR state.
esults from all permutations are used to calculate an empirical
-value of signiﬁcance for each CNVR-gene expression pair
Lanktree et al., 2009).
Associations with p-values of ≤0.05 after 5% fdr correction and
ermutation empirical p-values of ≤0.05 were considered signiﬁ-
ant. Genomic inﬂation was assessed by calculation of the lambda
genomic inﬂation factor) for each CNVR in R. The proportion of
ariance in gene expression explained by the CNVR was  calculated
sing the adjusted R2 obtained by the glm function in R. Differences
n gene expression variances across groups of transcripts were
alculated using the 2-sided Kolmogorov–Smirnov test (KS-test).
nrichment of eCNVRs for low frequency and over-representation
f genic eCNVRs was performed by conducting simulations. Sim-
lations were performed by generating 1000 randomized CNVRs
ets, matched for the CNVR frequency and of the same set at the
CNVR set. The randomized sets of CNVRs were sampled (without
eplacement) from all the tested CNVRs and based on the simula-
ions we obtained empirical p-values for enrichment. All reported
-values were 2-sided and within 95% conﬁdence interval.
Gene expression probes containing SNPs within their sequences
ere identiﬁed using the PLANdbAffy database (http://affymetrix2.
ioinf.fbb.msu.ru) and are highlighted in the results table.
The functional analysis was performed using the Wikipath-
ays and KEGG tools via the WebGestalt Gene Set Enrichment
atabase (http://bioinfo.vanderbilt.edu/webgestalt/). The enrich-
ent was calculated using a hypogeometric test using the human
enome as the background and all results were corrected for mul-
iple testing using the Bonferroni correction.
For comparisons of the results with previously reported eCNVRs
Luo et al., 2012; Schlattl et al., 2011; Stranger et al., 2007), we used
he eCNVRs which were signiﬁcant at linear regression fdr of 5%
Copy number variaon
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Fig. 1. Flowchart of studyesearch 79 (2014) 22–33
and permutation empirical p-value of ≤0.05 and compared these
to previously reported eCNVRs to check for overlaps between the
data sets.
To compare our results with previously identiﬁed brain
phenotype-associated CNVRs, we performed manual data min-
ing using NCBI PubMed to search for articles reporting signiﬁcant
CNVs identiﬁed in schizophrenia, major depressive disorder, bipo-
lar disorder and/or autism. We  limited our search to 7 large
association studies which comprised of at least 3000 patients
each (Ingason et al., 2011; International Schizophrenia Consortium,
2008; Levinson et al., 2011; McCarthy et al., 2009; Moreno-De-Luca
et al., 2010; Stefansson et al., 2008; Weiss et al., 2008).
3. Results
3.1. Identiﬁcation of CNVRs
A ﬂowchart of the study design and results is provided in
Fig. 1. Sample characteristics of the 72 individuals included in the
study are provided in Supplementary Table 1. While results on the
expression proﬁles of these samples have been reported previously
(Iwamoto et al., 2005, 2011), in the current study we assessed the
inﬂuence of CNVs on gene expression at the genome-wide scale.
Using the Agilent early access 450k array, after ﬁltering and pre-
processing, a total of 34,453 autosomal CNVs were identiﬁed in
the current samples, which were further grouped into 6836 unique
copy number variable regions (CNVRs) using criteria of at least 3
overlapping CNV probes. Among the 6836 CNVRs, 3549 were losses,
3136 were gains and 151 were complex (gains in some and losses
in others).
Of the CNVRs, 3656 (53.4%) were singletons while the remaining
3180 CNVRs were identiﬁed in at least two individuals (identical
CNVR start and end coordinates). For statistical analysis purposes,
the common criteria of 5% frequency was used to group the CNVRs
into 5058 (74%) rare/low frequency CNVRs and 1778 common
CNVRs (26%). Further, CNVRs were divided into two categories;
Gene expression  
Aﬀym etrix HU133A  arra y
11920 ﬁltered  probes
 arou nd CNVR
xpression probes
nalysis
 models 
ery rate
ermutao n 
alues
irs signiﬁcant
8 transc ripts
irs signiﬁcant
9 transcripts
n Flowchart
 design and results.
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isorder patients. (c) Distribution of the length of the CNVRs. (d) Number of probes
enic and intergenic. A total of 3051 of 6836 CNVRs (44.6%) were
genic’ CNVRs, i.e. CNVRs spanning a part of whole of the tran-
cript gene expression probe (with at least one base pair overlap
etween the regions) while the remaining CNVRs did not har-
or any known transcripts. The mean and median CNVR size was
6.5 kb and 11.9 kb respectively with average CNV segment num-
ers of 688 across all samples. The total combined CNVR burden
cross the individuals ranged between 11.6 and 72.4 Mb.  The total
umber of CNVR calls and distribution of CNVR length and probes
ncompassing CNVRs are depicted in Fig. 2.
.2. Inﬂuence of CNVRs on gene expression
Next, we sought to assess the inﬂuence of CNVRs on gene expres-
ion proﬁles in the human prefrontal cortex to identify functional
NVRs. To test the inﬂuence of CNVRs on the neighboring trans-
ripts we deﬁned a cis window of ±1 Mb  from the CNVR to identify
roximal transcripts (Fig. 3). For 6219 of the 6836 unique CNVRs,
t least one transcript was located within the ±1Mb  CNVR cis coor-
inates. Transcripts located within the cis coordinates amounted
o a total of 12,718 unique transcripts. For each CNVR, we  tested
he association between the CNVR and the transcripts within the
is coordinates using general linear models and adjusting for age,
ender and PMI  hours for the CNVR state. All results were correctedcross all samples. (b) Total CNVR calls across controls, schizophrenia and bipolar
passing CNVRs.
for multiple testing using 5% fdr. To avoid inﬂation due to outliers,
we repeated the association analysis by label-swapping adap-
tive permutations for each CNVR-expression probe pair. Results
of the permutations were compared with the linear regression
results and only CNVR-expression probe pairs signiﬁcant in both
tests were deemed as signiﬁcant. Average genomic inﬂation fac-
tor across all tested transcripts was  1.06, indicating no apparent
inﬂation.
A total of 4201 CNVR-probe pairs were signiﬁcant at p ≤ 0.05
and a total of 707 CNVR-probe pairs were signiﬁcant at 5%
fdr threshold in the linear regression analysis. These 707
pairs corresponded to a total of 339 unique expression CNVRs
(expression-inﬂuencing CNVRs or eCNVRs) and 448 unique expres-
sion probes. Of these, 583 CNVR-probe pairs (293 unique eCNVRs
and 429 unique expression probes) were also signiﬁcant after
permutation testing (Supplementary Table 2). Representative
examples of box plots of associations between CNVRs and gene
expression proﬁles of signiﬁcant eCNVRs are depicted in Fig. 4
and a list of the top 15 associations is given in Table 1. There-
fore, expression levels of 429 (3.4%) of 12,718 tested transcripts
were signiﬁcantly inﬂuenced by CNVRs after stringent corrections
for multiple testing and permutation. For 15 CNVRs overlapping a
transcript (inside pairs), a positive correlation between CNV state
and gene expression was obtained, as expected. On the other hand,
26 D. Mehta et al. / Neuroscience Research 79 (2014) 22–33
Fig. 3. Schematic ﬁgure of the cis window chosen for association testing of expression copy number variable regions (eCNVRs).
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 certain part of CNVR-gene expression correlations were nega-
ive. Such non-conventional types of eCNVRs seen in 242 (41%) of
he 293 CNVRs in this study have also been reported in previous
tudies (Luo et al., 2012; Schlattl et al., 2011; Stranger et al., 2007).
.3. Nature of the signiﬁcant brain eCNVRs
Of the 583 CNVR-probe pairs, we next interrogated the nature
f the 293 unique CNVRs in terms of frequency, size, genes
arbored, proportion of variance explained and functional anno-
ation (see Supplementary Table 2). Of the 293 eCNVRs, 239
81.6%) were rare/low frequency (<5% MAF) and the remaining
4 (18.4%) were common eCNVRs. There was a signiﬁcant
able 1
ist of top 15 signiﬁcant CNVR and gene expression associations.
CNVR ProbeSetID Chr Cytoband p val
Regr
q13.32 118726384 118815389 210065 s at 3 q13.32 2.09E
q11.21 20370979 20489827 222141 at 22 q11.21 1.38
q11.21 21709612 21905954 222141 at 22 q11.21 1.38
p13.2  112690773 112704407 213060 s at 1 p13.2 1.80E
q21.3  152555939 152586960 216701 at 1 q21.3 7.03E
q32.1  201177775 201181213 215168 at 1 q32.1 4.67
q34  112931419 112973293 205620 at 13 q34 2.63
p13.3  109749308 109757804 221874 at 1 p13.3 3.24
q12  34422129 34811416 218079 s at 17 q12 3.38
p13.3  110228105 110254473 207464 at 1 p13.3 1.72
q29  195409551 195448563 217110 s at 3 q29 3.17 gene expression proﬁles of signiﬁcant eCNVR.
over-representation of rare/low frequency CNVRs among the sig-
niﬁcant eCNVRs (p = 1.087 × 10−10). The size of the CNVRs ranged
between 234 bp and 1.65 Mb,  with an average length of 0.73 Mb.
Summary of the CNVR lengths are as follows; – ≤100 kb: 237,
101–500 kb: 48, 501 kb to 1 Mb:  7, and >1 Mb:  1. Of  the signiﬁ-
cant eCNVRs, 179 (61.1%) were genic while the remaining 38.9%
were non-genic, corresponding to a signiﬁcant over-representation
of genic CNVRs among the eCNVRs (p = 1.4 × 10−6). Such signiﬁcant
enrichment of low frequency and genic CNVRs was  also observed
when the analysis was  restricted to non-singleton CNVRs (CNVRs
robustly detected in at least 2 individuals) and when the CNVRs
were restricted to CNVR intervals containing at least 5 or more
probes.
ue Pair type Gene expression CNVR Start CNVR Stop
ession Transcript
-014 Outside UPK1B 118726384 118815389
E-013 Outside KLHL22 20370979 20489827
E-013 Outside KLHL22 21709612 21905954
-011 Outside CHI3L2 112690773 112704407
-011 Outside C1orf68 152555939 152586960
E-010 Outside TIMM17A 201177775 201181213
E-009 Outside F10 112931419 112973293
E-009 Inside KIAA1324 109749308 109757804
E-009 Outside GGNBP2 34422129 34811416
E-008 Outside AHCYL1 110228105 110254473
E-008 Outside MUC4 195409551 195448563
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Consistent with previous reports, no signiﬁcant correlations
etween CNVR-probe distance and frequency of signiﬁcant eCN-
Rs or the p-value of the association was observed. Such
orrelation was not seen even when stratifying the samples
nto low/high frequency CNVRs and genic/non-genic CNVRs
p > 0.05). The average proportion of variance in gene expression
xplained by the eCNVR was 26% across all signiﬁcant CNVR-probe
airs.
.4. Validation of the CNVRs and gene expression
We  next compared the brain eCNVRs to previously reported
CNVRs in lymphoblast cell lines (Luo et al., 2012; Schlattl et al.,
011; Stranger et al., 2007) or in the prefrontal cortex (Ye et al.,
012). Of the 293 eCNVRs, 29 (10%) were previously reported to
nﬂuence gene expression of nearby transcripts (see Supplemen-
ary Table 2).
Next, we compared the copy number data obtained by Agi-
ent CNV array with those obtained by Affymetix GeneChip Human
apping 500k SNP arrays for technical validation, which we  have
escribed previously (Iwamoto et al., 2011). Of the 731 autosomal
NVRs detected on the SNP array, we were able to detect 68 (9.3%)
n the CNV array, these included 2 singleton eCNVRs which were
igniﬁcantly associated with gene expression (see Supplementary
able 2).
For validation of gene expression data, we  used previously
eported data from Altar et al. (2008), where gene expression pro-
ling for the same prefrontal cortex samples was performed using
he same arrays and the same normalization protocols. We  assessed
he correlations between the gene expression proﬁles from the
urrent dataset and the published dataset. For the 429 probes sig-
iﬁcantly associated with CNVRs from Supplementary Table 2, an
verage correlation of 0.43 and median correlation of 0.40 was
bserved across all individuals. Using gene expression levels from
ltar and colleagues, we were able to successfully replicate CNVR-
ene expression associations for a handful of selected transcripts
ncluding PTPRN2, FHL2, SLC16A1, CH1DL and COMT genes, thereby
emonstrating the technical reliability of the data (see Supplemen-
ary Table 2).
.5. Overlap with loci associated with psychiatric disorders
While the eCNVR analysis was performed across all individ-
als due to limited power, the samples comprised of individuals
ith bipolar disorder (n = 23), schizophrenia (n = 23) and con-
rols (n = 26). Of the 293 signiﬁcant eCNVRs, 49 CNVRs were
ound only in bipolar disorder patients, 72 CNVRs were found
nly in schizophrenia patients, 70 CNVRs were found only in
ontrols and the remaining 122 CNVRs were found in indi-
iduals belonging to two or more groups. The average CNVR
urden and number of CNVRs were 32.23 kb and 621 regions
n schizophrenia patients, 32.81 kb and 623 regions in bipolar
atients and 30.12 kb and 588 regions in controls. No sig-
iﬁcant differences between the total CNVR burden, average
NVR burden and number of CNVRs were observed across the
roups.
able 2
athway analysis of transcripts inﬂuenced by CNVRs.
Over-represented pathways All transcripts 
Transcripts whose gene expression was regulated by CNVR
Corticotropin releasing hormone pathway 0.0430 
Transcripts located within CNVRs
Glutathione metabolism 0.0200 esearch 79 (2014) 22–33 27
3.6. Functional annotation of CNVR-inﬂuenced genes
Next, we interrogated the functional relevance of the signiﬁ-
cant CNVR-gene expression pairs using the Web-based Gene Set
Enrichment analysis (WebGestalt – Wikipathways and KEGG tools).
Among transcripts whose expression was  signiﬁcantly inﬂu-
enced by CNVRs, the corticotropin-releasing hormone pathway was
signiﬁcantly enriched and this enrichment was  also observed when
stratifying transcripts inﬂuenced by CNVRs in cases only or in con-
trols only (Table 2).
Functional annotation of genes overlapping copy number vari-
ants identiﬁed a signiﬁcant enrichment of transcripts implicated
within glutathione metabolism (p = 0.020) and oxidative stress
(p = 0.030) pathways in all genes (p = 0.020) and also only among
genes overlapping CNVRs in cases only (p = 0.0015 for glutathione
metabolism and p = 0.0031 for oxidative stress) but no such enrich-
ment was  observed when assessing only genes overlapping CNVRs
in controls only.
Hence, the functional relevance of the CNVR-encompassed
transcripts seems to be different in cases versus controls.
3.7. Comparison with loci associated with psychiatric disorders
We next compared the brain eCNVRs to previously reported
loci containing CNVRs which were shown to be associated with
schizophrenia, major depressive disorder, bipolar disorder and/or
autism (Supplementary Table 2). We  limited our search to loci from
7 large association studies (8 unique loci: 16p11.2, 1q21.1, 22q11.2,
3q29, 17q12, 16p13.1, 15q13.3 and 15q11.2) comprising of over
3000 cases per study. These 8 loci spanned approximately 44.6 Mb
(∼1.4% of whole genome). Of the 293 signiﬁcant eCNVRs, 72 (24.6%)
psychiatric-disorder associated CNVRs were found (Table 3). Of the
72 CNVRs, 19 were found only in schizophrenia patients, 21 were
found only in bipolar disorder patients and 19 were found only in
controls. Of the 19 CNVRs found only in controls, 7 were found in
a single control individual (C 15), due to unknown or unexplained
reasons, while the remaining CNVRs were found in independent
individuals. The average number of CNVRs and total CNVR burden
in this individual was well within the normal range (see Fig. 2b –
control 15) and we technically validated two  singleton CNVRs in
this individual (see Supplementary Table 2), thereby reducing the
possibility of sample issues such as DNA quality or hybridization
problems.
The 72 eCNVRs spanned seven of the eight candidate regions
including 16p11.2, 1q21.1, 22q11.2 (see Fig. 5), 3q29 (see Fig. 5),
15q11.2, 17q12 and 16p13.1 (Fig. 6 and Table 3). In a recent study,
CNVRs in 1q21.1 and 22q11.2 were shown to be signiﬁcantly asso-
ciated with dorsolateral prefrontal cortex gene expression levels
of nearby transcripts (Ye et al., 2012) while the other regions, to
the best of our knowledge, has not been shown to have functional
inﬂuence on gene expression regulation in the human brain.
4. DiscussionIn the current study, we interrogated the inﬂuence of CNVs
on gene expression in prefrontal cortex of post-mortem brain
samples to identify functional CNVs. Gene expression levels of
Only cases transcripts Only controls transcripts
0.0385 0.0198
0.0015 >0.050
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Table 3
List of eCNVRs within psychiatric trait-associated loci (International Schizophrenia Consortium, 2008; Levinson et al., 2011; McCarthy et al., 2009; Moreno-De-Luca et al.,
2010;  Stefansson et al., 2008).
CNVR CNVR type People ProbeSetID Psychiatric Permutations CNVR Start CNVR Stop GeneSymbol
Trait locus p value
q21.1 144322804 144400673 Gain bp 212392 s at 1q21.14,5 0.014808 144322804 144400673 PDE4DIP
q21.1  144672865 144709635 Gain bp 212392 s at 1q21.14,5 0.014808 144672865 144709635 PDE4DIP
q21.1  144952007 145074984 Gain bp 212392 s at 1q21.14,5 0.014808 144952007 145074984 PDE4DIP
q21.1  145190273 145292282 Gain bp 212392 s at 1q21.14,5 0.014808 145190273 145292282 PDE4DIP
q21.1 145293607 145368437 Loss bp 209207 s at 1q21.14,5 0.006770 145293607 145368437 SEC22B
q21.1 145312073 145367945 Gain bp,bp,con*,con 206766 at 1q21.14,5 0.003476 145312073 145367945 ITGA10
q21.1  145312073 145367945 Gain bp,bp,con*,con 214113 s at 1q21.14,5 0.010387 145312073 145367945 RBM8A
q21.1  145312073 145367945 Gain bp,bp,con*,con 209206 at 1q21.14,5 0.018087 145312073 145367945 SEC22B
q21.1  145626237 145746971 Loss bp 209207 s at 1q21.14,5 0.006718 145626237 145746971 SEC22B
q21.1  146034981 146039673 Loss con 214113 s at 1q21.14,5 0.002943 146034981 146039673 RBM8A
q21.1 146215885 146231981 Gain bp,bp,con* 212539 at 1q21.14,5 0.009246 146215885 146231981 CHD1L
q21.1 146215885 146231981 Gain bp,bp,con* 214474 at 1q21.14,5 0.046320 146215885 146231981 PRKAB2
q21.1  146215885 146231981 Gain bp,bp,con* 205776 at 1q21.14,5 0.005915 146215885 146231981 FMO5
q21.1  146215885 146231981 Gain bp,bp,con* 206766 at 1q21.14,5 0.003218 146215885 146231981 ITGA10
q21.1  146215885 146231981 Gain bp,bp,con* 212742 at 1q21.14,5 0.012921 146215885 146231981 RNF115
q21.1 146215885 146231981 Gain bp,bp,con* 215300 s at 1q21.14,5 0.046230 146215885 146231981 FMO5
q29  195215347 195232654 Gain 2bp,sz,2con 221536 s at 3q294 0.015525 195215347 195232654 LSG1
q29  195215347 195237188 Gain sz,sz 217109 at 3q294 0.008881 195215347 195237188 MUC4
q29  195341670 195453587 Gain sz 212477 at 3q294 0.003827 195341670 195453587 ACAP2
q29  195341670 195743252 Gain sz 208878 s at 3q294 0.014808 195341670 195743252 PAK2
q29 195341813 195725193 Gain con 212476 at 3q294 0.004947 195341813 195725193 ACAP2
q29  195341813 195725193 Gain con 208877 at 3q294 5.22E-005 195341813 195725193 PAK2
q29  195341813 195725193 Gain con 204210 s at 3q294 0.001016 195341813 195725193 PCYT1A
q29  195344712 195477486 Gain sz 203838 s at 3q294 0.003567 195344712 195477486 TNK2
q29  195344712 195477486 Gain sz 204209 at 3q294 0.014120 195344712 195477486 PCYT1A
q29  195344712 195477486 Gain sz 212476 at 3q294 0.004968 195344712 195477486 ACAP2
q29  195344712 195477486 Gain sz 221536 s at 3q294 0.001392 195344712 195477486 LSG1
q29 195393418 195452775 Gain con 204210 s at 3q294 0.001016 195393418 195452775 PCYT1A
q29  195393418 195452775 Gain con 212476 at 3q294 0.004947 195393418 195452775 ACAP2
q29  195409551 195448563 Loss bp 212476 at 3q294 0.004287 195409551 195448563 ACAP2
q29  195409551 195448563 Loss bp 216439 at 3q294 0.005625 195409551 195448563 TNK2
q29  195409551 195448563 Loss bp 217110 s at 3q294 9.47E-007 195409551 195448563 MUC4
q29 195411543 195448616 Complex con,con,sz 207332 s at 3q294 0.011657 195411543 195448616 TFRC
q29  195411543 195448616 Complex con,con,sz 208691 at 3q294 0.015725 195411543 195448616 TFRC
q29  195506071 195515379 Gain 4bp,2sz,3con 207332 s at 3q294 0.054061 195506071 195515379 TFRC
q29  195506071 195516643 Gain 3sz,1bp,1con 212477 at 3q294 0.005181 195506071 195516643 ACAP2
q29  195648611 195747915 Gain sz 212477 at 3q294 0.003827 195648611 195747915 ACAP2
q29  195663926 195725193 Loss bp,bp,con 212477 at 3q294 0.014808 195663926 195725193 ACAP2
q29  196555515 196559209 Loss 8bp,3sz,8con 203839 s at 3q294 0.012921 196555515 196559209 TNK2
q29 196759662 196762173 Loss sz 207332 s at 3q294 0.000185 196759662 196762173 TFRC
q29  196759662 196762173 Loss sz 208691 at 3q294 0.004467 196759662 196762173 TFRC
q29  197347418 197394189 Loss 3sz,2bp 208877 at 3q294 0.000305 197347418 197394189 PAK2
q29  197347418 197394189 Loss 3sz,2bp 208877 at 3q294 0.000305 197347418 197394189 PAK2
q29  197603683 197605592 Gain sz 211715 s at 3q294 0.010798 197603683 197605592 BDH1
q29  197603683 197605592 Gain sz 212733 at 3q294 4.15E-006 197603683 197605592 KIAA0226
q29  197603683 197605592 Gain sz 220041 at 3q294 0.004968 197603683 197605592 PIGZ
q29  197825694 197833212 Loss sz,bp 212733 at 3q294 0.006171 197825694 197833212 KIAA0226
q29  197825901 197832592 Gain con,bp 214739 at 3q294 0.006171 197825901 197832592 LRCH3
q29  197825901 197832592 Gain con,bp 213687 s at 3q294 0.014935 197825901 197832592 RPL35A
q29  197895169 197896197 Gain 10sz,6bp,7con 212733 at 3q294 0.051563 197895169 197896197 KIAA0226
q11.2  22303902 22372338 Loss con 214876 s at 15q11.227 0.003155 22303902 22372338 TUBGCP5
q11.2  22318597 22348005 Loss con 212133 at 15q11.227 0.003062 22318597 22348005 NIPA2
p11.2  28390355 28437534 Gain bp 221822 at 16p11.25,6 0.012273 28390355 28437534 CCDC101
p11.2  28612132 28615866 Gain sz 212808 at 16p11.25,6 0.008063 28612132 28615866 NFATC2IP
p11.2  30200517 30220479 Gain con* 221864 at 16p11.25,6 0.003399 30200517 30220479 ORAI3
p11.2  30200517 30220479 Gain con* 212275 s at 16p11.25,6 0.004775 30200517 30220479 SRCAP
p11.2  30200517 30220479 Gain con* 45653 at 16p11.25,6 0.014873 30200517 30220479 KCTD13
p11.2  30200517 30220479 Gain con* 207684 at 16p11.25,6 0.003057 30200517 30220479 TBX6
p11.2  30200517 30220479 Gain con* 200961 at 16p11.25,6 0.005915 30200517 30220479 SEPHS2
p11.2  30200517 30220479 Gain con* 201253 s at 16p11.25,6 0.001670 30200517 30220479 CDIPT
p11.2  30200517 30220479 Gain con* 202256 at 16p11.25,6 0.005277 30200517 30220479 CD2BP2
p11.2 30200517 30220479 Gain con* 204876 at 16p11.25,6 0.007028 30200517 30220479 ZNF646
p11.2  30200517 30220479 Gain con* 204878 s at 16p11.25,6 0.010941 30200517 30220479 TAOK2
p11.2  30200517 30220479 Gain con* 205744 at 16p11.25,6 0.000305 30200517 30220479 DOC2A
p11.2  30200517 30220479 Gain con* 209083 at 16p11.25,6 0.000158 30200517 30220479 CORO1A
p11.2  30200517 30220479 Gain con* 214226 at 16p11.25,6 0.000264 30200517 30220479 PRSS53
p11.2  30200517 30220479 Gain con* 217949 s at 16p11.25,6 0.003144 30200517 30220479 VKORC1
p11.2  30200517 30220479 Gain con* 218300 at 16p11.25,6 0.014342 30200517 30220479 C16orf53
p11.2  30200517 30220479 Gain con* 219072 at 16p11.25,6 0.005495 30200517 30220479 BCL7 C
p11.2  30200517 30220479 Gain con* 219781 s at 16p11.25,6 0.000235 30200517 30220479 ZNF771
p11.2  30200517 30220479 Gain con* 221968 s at 16p11.25,6 0.015791 30200517 30220479 ZNF771
p11.2  32164104 33816677 Gain bp 219540 at 16p11.25,6 0.006770 32164104 33816677 ZNF267
p13.11 15011919 15029273 Gain con 222204 s at 16p13.125 0.014769 15011919 15029273 RRN3
p13.13 12020113 12036399 Gain bp 205101 at 16p13.125 0.014502 12020113 12036399 CIITA
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CNVR CNVR type People ProbeSetID Psychiatric Permutations CNVR Start CNVR Stop GeneSymbol
Trait locus p value
p13.13 12020113 12036399 Gain bp 210001 s at 16p13.125 1.29E-005 12020113 12036399 SOCS1
q12 34407079 34662164 Gain con* 212186 at 17q1226 1.93E-005 34407079 34662164 ACACA
q12  34407079 34662164 Gain con* 219885 at 17q1226 2.21E-005 34407079 34662164 SLFN12
q12  34407079 34662164 Gain con* 1405 i at 17q1226 0.000985 34407079 34662164 CCL5
q12  34407079 34662164 Gain con* 204655 at 17q1226 0.005086 34407079 34662164 CCL5
q12  34407079 34662164 Gain con* 207354 at 17q1226 0.005086 34407079 34662164 CCL16
q12  34407079 34662164 Gain con* 209924 at 17q1226 0.006012 34407079 34662164 CCL18
q12 34407079 34662164 Gain con* 209965 s at 17q1226 0.000290 34407079 34662164 RAD51L3
q12 34407079 34662164 Gain con* 212544 at 17q1226 0.000364 34407079 34662164 ZNHIT3
q12  34407079 34662164 Gain con* 218079 s at 17q1226 0.001911 34407079 34662164 GGNBP2
q12  34407079 34662164 Gain con* 219320 at 17q1226 0.009997 34407079 34662164 MYO19
q12  34407079 34662164 Gain con* 220499 at 17q1226 0.001219 34407079 34662164 FNDC8
q12  34407079 34662164 Gain con* 32128 at 17q1226 0.006474 34407079 34662164 CCL18
q12 34408772 34646159 Gain sz 206230 at 17q1226 0.014502 34408772 34646159 LHX1
q12  34422129 34811416 Gain sz 210548 at 17q1226 0.003787 34422129 34811416 CCL23
q12  34422129 34811416 Gain sz 1405 i at 17q1226 0.003569 34422129 34811416 CCL5
q12  34422129 34811416 Gain sz 200615 s at 17q1226 0.018005 34422129 34811416 AP2B1
q12 34422129 34811416 Gain sz 207343 at 17q1226 2.38E-005 34422129 34811416 LYZL6
q12  34422129 34811416 Gain sz 209924 at 17q1226 0.000753 34422129 34811416 CCL18
q12  34422129 34811416 Gain sz 209938 at 17q1226 0.004331 34422129 34811416 TADA2A
q12  34422129 34811416 Gain sz 212186 at 17q1226 8.94E-005 34422129 34811416 ACACA
q12  34422129 34811416 Gain sz 212544 at 17q1226 7.39E-005 34422129 34811416 ZNHIT3
q12  34422129 34811416 Gain sz 218079 s at 17q1226 1.36E-007 34422129 34811416 GGNBP2
q12  34422129 34811416 Gain sz 218756 s at 17q1226 0.004968 34422129 34811416 DHRS11
q12 34422129 34811416 Gain sz 220499 at 17q1226 0.000417 34422129 34811416 FNDC8
q12  34422129 34811416 Gain sz 32128 at 17q1226 0.000252 34422129 34811416 CCL18
q12  34488357 34760365 Gain con 210548 at 17q1226 0.002623 34488357 34760365 CCL23
q12  34605880 34643115 Gain con 200612 s at 17q1226 0.011851 34605880 34643115 AP2B1
q12  34605880 34643115 Gain con 212186 at 17q1226 0.014502 34605880 34643115 ACACA
q12 34611572 34615943 Gain con 200612 s at 17q1226 0.011851 34611572 34615943 AP2B1
q12  34611572 34615943 Gain con 212186 at 17q1226 0.014502 34611572 34615943 ACACA
q12 34764374 34790180 Loss sz 210549 s at 17q1226 0.007902 34764374 34790180 CCL23
q12  34791790 34806889 Gain sz 210549 s at 17q1226 0.007902 34791790 34806889 CCL23
q12  35779149 35780902 Loss bp 210320 s at 17q1226 6.21E-006 35779149 35780902 DDX52
q12  36351950 36385101 Loss con* 218655 s at 17q1226 0.004733 36351950 36385101 CWC25
q12  36351950 36385101 Loss con* 200618 at 17q1226 0.012387 36351950 36385101 LASP1
q12 36351950 36385101 Loss con* 201080 at 17q1226 0.000339 36351950 36385101 PIP4K2B
q12  36351950 36385101 Loss con* 201081 s at 17q1226 0.003507 36351950 36385101 PIP4K2B
q12  36351950 36385101 Loss con* 201400 at 17q1226 0.005039 36351950 36385101 PSMB3
q12  36351950 36385101 Loss con* 210185 at 17q1226 0.008384 36351950 36385101 CACNB1
q12  36351950 36385101 Loss con* 212186 at 17q1226 1.93E-005 36351950 36385101 ACACA
q12  36351950 36385101 Loss con* 221937 at 17q1226 0.016260 36351950 36385101 SYNRG
q11.21 18618723 18621135 Loss sz 202099 s at 22q11.24,5 0.007575 18618723 18621135 DGCR2
q11.21 18734360 18862822 Loss bp 214371 at 22q11.24,5 0.009124 18734360 18862822 TSSK2
q11.21 18734360 18862822 Loss bp 220762 s at 22q11.24,5 0.004501 18734360 18862822 GNB1L
q11.21 19893805 19895800 Loss bp 214371 at 22q11.24,5 0.009124 19893805 19895800 TSSK2
q11.21 19893805 19895800 Loss bp 220762 s at 22q11.24,5 0.004501 19893805 19895800 GNB1L
q11.21 20339345 20362501 Loss bp 220762 s at 22q11.24,5 0.004501 20339345 20362501 GNB1L
q11.21 20370979 20461985 Gain bp 214406 s at 22q11.24,5 0.003467 20370979 20461985 SLC7A4
q11.21 20370979 20461985 Gain bp 220762 s at 22q11.24,5 0.004501 20370979 20461985 GNB1L
q11.21 20370979 20489827 Loss con* 207081 s at 22q11.24,5 3.15E-005 20370979 20489827 PI4KA
q11.21 20370979 20489827 Loss con* 212180 at 22q11.24,5 0.003267 20370979 20489827 CRKL
q11.21 20370979 20489827 Loss con* 204482 at 22q11.24,5 0.012431 20370979 20489827 CLDN5
q11.21 20370979 20489827 Loss con* 205576 at 22q11.24,5 0.007335 20370979 20489827 SERPIND1
q11.21 20370979 20489827 Loss con* 205881 at 22q11.24,5 0.009217 20370979 20489827 ZNF74
q11.21 20370979 20489827 Loss con* 206880 at 22q11.24,5 0.005912 20370979 20489827 P2RX6
q11.21 20370979 20489827 Loss con* 207662 at 22q11.24,5 0.001885 20370979 20489827 TBX1
q11.21 20370979 20489827 Loss con* 208818 s at 22q11.24,5 0.011028 20370979 20489827 COMT
q11.21 20370979 20489827 Loss con* 211147 s at 22q11.24,5 0.015425 20370979 20489827 P2RX6
q11.21 20370979 20489827 Loss con* 213981 at 22q11.24,5 2.02E-005 20370979 20489827 COMT
q11.21 20370979 20489827 Loss con* 218492 s at 22q11.24,5 0.003155 20370979 20489827 THAP7
q11.21 20370979 20489827 Loss con* 219811 at 22q11.24,5 0.010840 20370979 20489827 DGCR8
q11.21 20370979 20489827 Loss con* 221838 at 22q11.24,5 0.016453 20370979 20489827 KLHL22
q11.21 20370979 20489827 Gain con* 222141 at 22q11.24,5 1.02E-011 20370979 20489827 KLHL22
q11.21 20626904 20648019 Loss con 205576 at 22q11.24,5 0.000367 20626904 20648019 SERPIND1
q11.21 20648172 20715558 Gain con 211177 s at 22q11.24,5 0.000771 20648172 20715558 TXNRD2
q11.21 20648172 20715558 Gain con 218475 at 22q11.24,5 0.011596 20648172 20715558 TRMT2A
q11.21 20648172 20715558 Gain con 91617 at 22q11.24,5 0.000145 20648172 20715558 DGCR8
q11.21 21455772 21667502 Loss bp 221349 at 22q11.24,5 0.002569 21455772 21667502 VPREB1
q11.21 21455772 21667502 Loss bp 214406 s at 22q11.24,5 0.003467 21455772 21667502 SLC7A4
q11.21 21668908 21709656 Gain sz 216301 at 22q11.24,5 1.18E-005 21668908 21709656 LOC100287927
q11.21 21670977 21905954 Gain sz 216911 s at 22q11.24,5 0.000279 21670977 21905954 HIC2
q11.21 21708235 21905954 Gain sz 217180 at 22q11.24,5 0.017219 21708235 21905954
q11.21 21709612 21905954 Loss con* 204086 at 22q11.24,5 0.004800 21709612 21905954 PRAME
q11.21 21709612 21905954 Loss con* 206064 s at 22q11.24,5 0.018360 21709612 21905954 PPIL2
q11.21 21709612 21905954 Loss con* 206880 at 22q11.24,5 0.005912 21709612 21905954 P2RX6
30 D. Mehta et al. / Neuroscience Research 79 (2014) 22–33
Table 3 (Continued )
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q11.21 21709612 21905954 Loss con* 212180 at 22q11.24,5 0.003267 21709612 21905954 CRKL
q11.21 21709612 21905954 Loss con* 218492 s at 22q11.24,5 0.003155 21709612 21905954 THAP7
q11.21 21709612 21905954 Loss con* 205881 at 22q11.24,5 0.009217 21709612 21905954 ZNF74
q11.21 21709612 21905954 Loss con* 207081 s at 22q11.24,5 3.15E-005 21709612 21905954 PI4KA
q11.21 21709612 21905954 Loss con* 211147 s at 22q11.24,5 0.015425 21709612 21905954 P2RX6
q11.21 21709612 21905954 Loss con* 221838 at 22q11.24,5 0.016453 21709612 21905954 KLHL22
q11.21 21709612 21905954 Loss con* 222141 at 22q11.24,5 1.02E-011 21709612 21905954 KLHL22
q11.21 21709612 21905954 Loss con* 200684 s at 22q11.24,5 0.007571 21709612 21905954 UBE2L3
q11.21 21709612 21905954 Loss con* 205576 at 22q11.24,5 0.007335 21709612 21905954 SERPIND1
q11.21 21709612 21905954 Loss con* 212271 at 22q11.24,5 0.000261 21709612 21905954 MAPK1
q11.21 21711906 21905954 Gain bp 214406 s at 22q11.24,5 0.003467 21711906 21905954 SLC7A4
q11.21 21711906 21905954 Gain bp 215048 at 22q11.24,5 0.018037 21711906 21905954 ZNF280B
q11.21 21711906 21905954 Gain bp 221349 at 22q11.24,5 0.002569 21711906 21905954 VPREB1
q11.22 22605295 22630082 Gain bp 211655 at 22q11.24,5 0.018087 22605295 22630082 LOC100287927
q11.22 23241489 23252126 Gain sz 215036 at 22q11.24,5 0.016135 23241489 23252126
q11.22  23242646 23248046 Gain sz 217180 at 22q11.24,5 0.017219 23242646 23248046
q11.23  23805014 23825653 Gain sz 203815 at 22q11.24,5 0.007688 23805014 23825653 GSTT1
q11.23 24271987 24343125 Loss sz 203815 at 22q11.24,5 0.007688 24271987 24343125 GSTT1
q11.23 24278085 24341961 Loss sz 202624 s at 22q11.24,5 0.006683 24278085 24341961 CABIN1
q11.23 24278085 24341961 Loss sz 214623 at 22q11.24,5 0.008420 24278085 24341961 FBXW4P1
q11.23 24291835 24345621 Gain con* 204993 at 22q11.24,5 5.26E-005 24291835 24345621 GNAZ
q11.23 24291835 24345621 Gain con* 217668 at 22q11.24,5 0.000836 24291835 24345621 C22orf36
q11.23 24291835 24345621 Gain con* 215202 at 22q11.24,5 0.001560 24291835 24345621 LOC91316
q11.23 24291835 24345621 Gain con* 203878 s at 22q11.24,5 0.017484 24291835 24345621 MMP11
q11.23 24291835 24345621 Gain con* 205582 s at 22q11.24,5 4.46E-005 24291835 24345621 GGT5
q11.23 24291835 24345621 Gain con* 202929 s at 22q11.24,5 0.003827 24291835 24345621 DDT
q11.23 24291835 24345621 Gain con* 211471 s at 22q11.24,5 0.000417 24291835 24345621 RAB36
q11.23 24291835 24345621 Gain con* 217871 s at 22q11.24,5 3.15E-005 24291835 24345621 MIF
q11.23 24329367 24398674 Loss bp 212167 s at 22q11.24,5 0.018093 24329367 24398674 SMARCB1
q11.23 24341917 24400174 Loss bp 207215 at 22q11.24,5 0.015425 24341917 24400174 GSTTP1
q11.23 24341917 24400174 Loss bp 203877 at 22q11.24,5 0.002009 24341917 24400174 MMP11
q11.23 24341917 24400174 Loss bp 221108 at 22q11.24,5 0.000987 24341917 24400174 C22orf43
q11.23 24341917 24400174 Loss bp 206532 at 22q11.24,5 2.32E-006 24341917 24400174
q11.23  24341917 24400174 Loss bp 215816 at 22q11.24,5 3.15E-005 24341917 24400174 LOC91316
q11.23 24341917 24400174 Loss bp 220507 s at 22q11.24,5 0.017079 24341917 24400174 UPB1
q11.23 24344364 24398674 Loss con 211471 s at 22q11.24,5 0.016695 24344364 24398674 RAB36
q11.23 24344364 24398674 Loss con 204993 at 22q11.24,5 0.003924 24344364 24398674 GNAZ
q11.23 24344364 24398674 Loss con 217871 s at 22q11.24,5 0.013295 24344364 24398674 MIF
q11.23 24344364 24398674 Loss con 202315 s at 22q11.24,5 0.001560 24344364 24398674 BCR
q11.23 24344364 24398674 Loss con 217223 s at 22q11.24,5 0.000426 24344364 24398674 BCR
q11.23 24344364 24398674 Loss con 37652 at 22q11.24,5 0.009212 24344364 24398674 CABIN1
q11.23 24356690 24369021 Gain con* 215202 at 22q11.24,5 0.001560 24356690 24369021 LOC91316
q11.23 24356690 24369021 Gain con* 217668 at 22q11.24,5 0.000836 24356690 24369021 C22orf36
q11.23 24356690 24369021 Gain con* 204993 at 22q11.24,5 5.26E-005 24356690 24369021 GNAZ
q11.23 24356690 24369021 Gain con* 211471 s at 22q11.24,5 0.000417 24356690 24369021 RAB36
q11.23 24356690 24369021 Gain con* 205582 s at 22q11.24,5 4.46E-005 24356690 24369021 GGT5
q11.23 24356690 24369021 Gain con* 217871 s at 22q11.24,5 3.15E-005 24356690 24369021 MIF
q11.23 24356690 24369021 Gain con* 202929 s at 22q11.24,5 0.003827 24356690 24369021 DDT
q11.23 24356690 24369021 Gain con* 203878 s at 22q11.24,5 0.017484 24356690 24369021 MMP11
q11.23 25756694 25775816 Gain bp 220507 s at 22q11.24,5 0.017079 25756694 25775816 UPB1
q11.23 25756694 25775816 Gain bp 204183 s at 22q11.24,5 0.001594 25756694 25775816 ADRBK2
q11.23 25756694 25775816 Gain bp 204184 s at 22q11.24,5 0.002150 25756694 25775816 ADRBK2
x = in LCLs and xxx = in brain tissue; sz = schizophrenia, bp = bipolar, con = control, con* = control outlier C 15.
Fig. 5. Signiﬁcant eCNVRs previously shown to be associated with schizophrenia or autism-spectrum disorders within candidate loci 3q29 and 22q11.2.
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wig. 6. Log ratio plots of 3 examples of signiﬁcant eCNVRs within candidate loci 1
ndicate  losses and green dots indicate gains. Blue dots indicate other CNVRs with
ene  expression levels. (a) 15q11.2, (b) 16p13, and (c) 22q11.2.
29 transcripts were signiﬁcantly associated with CNVR state
fter corrections for multiple testing and permutation. This corre-
ponded to 583 CNVR-probe pairs (293 unique eCNVRs). Among
he eCNVRs, a signiﬁcant over-representation of rare/low fre-
uency CNVRs (p = 1.087 × 10−10) and gene-harboring/genic CNVRs
p = 1.4 × 10−6) was observed. Overrepresentation of rare/low fre-
uency CNVs among eCNVRs is interesting from an evolutionary
oint of view. A signiﬁcant proportion of variance in gene expres-
ion could be explained by the eCNVR, with an average of 26%
ariance across the transcripts. A large proportion of negative corre-
ations observed, demonstrated the complex relationship between
NVs and gene expression. Regulatory mechanisms such as epista-
is or auto-regulatory feedback mechanisms at the level of the gene
ight explain the negative correlations. For instance, deletions
hat affect silencers or insulator elements can result in increased
ene expression of the transcript (Weischenfeldt et al., 2013). Com-
arisons of the brain eCNVRs identiﬁed in the current study to
reviously reported eCNVRs yielded a 10% overlap, thereby pro-
iding a replication for these eCNVRs despite the differences in
amples and study design between the studies.
Functional annotation of transcripts associated with CNVRs
evealed a signiﬁcant enrichment of corticotrophin-releasing hor-
one pathway across all samples, and also upon stratiﬁcation by
ases and controls. However, genes overlapping CNVRs only in
ases but not in controls were enriched for glutathione metabolism
nd oxidative stress. Glutathione is a major antioxidant in the brain
nd plays a crucial role in protecting against oxidative damage.
t is reported that glutathione levels were decreased (Gawryluk
t al., 2001) and oxidative stress is enhanced (Ng et al., 2008) in
chizophrenia and bipolar disorder, and mood stabilizers increases
lutathione S-transferase (Wang et al., 2004). Thus, altered glu-
athione and oxidative stress pathways due to CNV might be related
o pathophysiology of bipolar disorder and schizophrenia.
To test whether the eCNVRs were located within psychiatric
henotype-associated loci, we performed a literature search to
dentify CNVRs robustly associated with psychiatric diseases and
ystematically checked these loci (n = 8 unique loci). The 293
igniﬁcant eCNVRs identiﬁed in this study included 72 (24.6%)
sychiatric-disorder associated eCNVRs within these 8 loci, indi-
ating that copy number variants in these loci might be directly
nvolved in transcriptional regulation in the brain. These eCN-
Rs encompassed 7 (16p11.2, 1q21.1, 22q11.2, 3q29, 15q11.2,
7q12 and 16p13.1) of the 8 tested loci. Of the 72 eCNVRs, 19
NVRs were identiﬁed only in schizophrenia patients and 21 CNVRs
ere observed only in bipolar disorder patients. A total of 19.2, 16p13 and 22q11.2 previously associated with psychiatric disorders. Red dots
 individual which were detected but these were not signiﬁcantly associated with
CNVRs were found only in controls of which 7 were found in a
single control individual (C 15). For C 15, the CNVR burden was
within the range of that detected across all other samples and by
technically validating two  CNVRs harbored by this individual, we
excluded the possibility of sample contamination or hybridization
artifacts. This control individual however due to unknown or unex-
plained reasons harbored several of the known bipolar disorder and
schizophrenia-associated CNVRs. For the 15q13.3 region, we  did
not identify any CNVRs associated with gene expression levels.
Recently, Ye and colleagues identiﬁed that CNVs in 1q21.1 and
22q11.2 were signiﬁcantly associated with expression levels of
nearby transcripts in dorsolateral prefrontal cortex (Ye et al., 2012).
We found an association between a CNVR in 1q21.1 and CHD1L as
reported by Ye and colleagues and in the current study the same
CNVR was  also associated with gene expression levels of FMO5,
PRKAB2, RNF115 and ITGA10. These CNVRs were present in 2 bipo-
lar disorder patients and control C 15. Additionally, we identiﬁed
8 further CNVRs in 1q21.1 (6 only in bipolar patients, one in 2
bipolar patients, one control and control C 15 and one only in con-
trol C 15) signiﬁcantly associated with gene expression levels of
PDE4DIP, SEC22B, RBM8A, PRKAB2 and ITGA10. In line with Ye
et al. (2012), we observed a signiﬁcant association of a 22q11.2
CNVR in control C 15 with COMT gene expression for two sep-
arate gene expression probes. In addition, our data pointed also
toward the PI4KA gene within this locus whose expression was
signiﬁcantly associated with 2 CNVRs (both in control C 15) in the
22q11.2 locus. The initial study by Saito and colleagues (Saito et al.,
2003) identiﬁed a link between PI4KA and 22q11.2-linked psychi-
atric disorders. The PI4KA gene encodes a phosphatidylinositol (PI)
4-kinase which catalyses the ﬁrst committed step in the biosyn-
thesis of phosphatidylinositol 4,5-bisphosphate. Incorporating the
results of all association of PI4KA with schizophrenia till date has
yielded mixed results and the link between PI4KA and psychiatric
disorders remains unclear (Kanahara et al., 2009; Saito et al., 2003;
Vorstman et al., 2009). This is the ﬁrst report highlighting a func-
tional link between CNVRs within the 22q11.2 locus and PI4KA
gene expression in the human brain, suggesting that PI4KA might
indeed be related to 22q11.2-related psychiatric diseases. In sum-
mary, results of the current study replicate the ﬁndings by Ye and
colleagues that 1q21.1 and 22q11.2 may  be involved in pathophy-
siology of psychiatric disorders by affecting gene expression levels
in the brain.
For an additional ﬁve candidate regions reported to be associ-
ated with schizophrenia and/or autism-spectrum disorders (3q29,
15q11.2, 16p11.2, 16p13.1 and 17q12), for the ﬁrst time we
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dentiﬁed signiﬁcant functional inﬂuence of CNVRs on prefrontal
ortex gene expression, implicating that these loci confer a risk of
sychiatric disorders by affecting gene expression in the brain. Of
ote was the ﬁnding of 6 CNVRs within the 16p11.2 locus that sig-
iﬁcantly inﬂuenced gene expression proﬁles of several transcripts
ncluding CORO1A, TAOK2, DOC2A, SEPHS2 and CDIPT transcripts
n the human prefrontal cortex. Both deletions and duplications
ithin the 16p11.2 region have been signiﬁcantly associated with
chizophrenia, autism and autism-spectrum disorders in several
tudies (Levinson et al., 2011; Luo et al., 2012; McCarthy et al., 2009;
eiss et al., 2008).
The current study has several strengths and limitations. On one
and, due to the small sample size, the power of this study is limited
nd replication of these ﬁndings in larger cohorts is warranted.
onetheless, several of the results reported in this study overlap
ith previous reports, hence for these ﬁndings our study provides
 replication of the previous results. Furthermore, 9.3% of autoso-
al  CNVRs detected on the SNP array were successfully detected
n the same individuals using the CNV arrays, thereby providing
 technical validation of these data. Also, we acknowledge that
ossible confounding effects of medication or smoking or other
llness-related factors are difﬁcult to account for and might inﬂu-
nce the gene expression proﬁles. To the best of our knowledge
his is the most comprehensive genome-wide CNV-gene expression
ssociation analysis performed so far and the ﬁrst genome-wide
ypothesis-free study assessing the inﬂuence of rare/low frequency
NVs on gene expression in the human brain. Other strengths of this
tudy include assessment of brain tissue which is more relevant for
sychiatric diseases and utilization of brain samples with high pH
evels to increase reliability of the data.
In conclusion, we used a hypothesis-free approach to iden-
ify brain CNVRs which signiﬁcantly inﬂuence genome-wide
ene expression levels of nearby transcripts. Such an integra-
ive approach is important to prioritize functional CNVs which
xhibit downstream consequences at the gene expression level
ver other CNVs. This study demonstrates that CNVRs inﬂuencing
ene expression in the human prefrontal cortex are signiﬁcantly
nriched for rare/low frequency CNVs and gene harboring CNVs.
ur results replicate previous ﬁndings of associations at 1q21.1
nd 22q11.2 regions and suggest the possible role of candi-
ates within the 3q29, 15q11.2, 16p11.2, 16p13.1 and 17q12
oci in schizophrenia and bipolar disorder. Future studies sur-
eying different types of genetic variation in diverse tissues are
equired to fully comprehend human phenotypic diversity and dis-
ase.
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